Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 8/20 | 0.47 |
| ▸ | USP7 | Q93009 | 3/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 4/20 | 0.41 |
| ▸ | VRK1 | Q99986 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580922 | 0.82 | MAP4K4 (0.54) | MAP4K4USP7CHEK2FYN | |
| SCHEMBL4582430 | 0.81 | CHEK2 (0.44) | MAP4K4USP7CHEK2FYNVRK1 | |
| SCHEMBL625738 | 0.76 | NTRK1 (0.50) | MAP4K4USP7CHEK2FYNMKNK1 | |
| SCHEMBL29973001 | 0.74 | MAP4K4 (0.56) | MAP4K4USP7CHEK2CYP1A2KCNH2 | |
| SCHEMBL17532997 | 0.73 | NTRK1 (0.51) | MAP4K4USP7CHEK2FYN | |
| SCHEMBL28032602 | 0.71 | CYP2A6 (0.57) | MAP4K4USP7CHEK2FYN | |
| SCHEMBL4582434 | 0.71 | ADORA1 (0.49) | MAP4K4CHEK2FYN | |
| SCHEMBL623436 | 0.70 | BTK (0.50) | MAP4K4 | |
| SCHEMBL29476657 | 0.70 | BTK (0.50) | MAP4K4 | |
| Hydrochloric Acid SCHEMBL4359853 | 0.70 | CYP2A6 (0.55) | MAP4K4USP7CHEK2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | MAP4K4 354/4885USP7 2058/4885CHEK2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.